JP2013515079A5 - - Google Patents

Download PDF

Info

Publication number
JP2013515079A5
JP2013515079A5 JP2012546164A JP2012546164A JP2013515079A5 JP 2013515079 A5 JP2013515079 A5 JP 2013515079A5 JP 2012546164 A JP2012546164 A JP 2012546164A JP 2012546164 A JP2012546164 A JP 2012546164A JP 2013515079 A5 JP2013515079 A5 JP 2013515079A5
Authority
JP
Japan
Prior art keywords
therapeutic agent
agent according
seq
antibody
pseudomonas aeruginosa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012546164A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013515079A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/061636 external-priority patent/WO2011087799A1/en
Publication of JP2013515079A publication Critical patent/JP2013515079A/ja
Publication of JP2013515079A5 publication Critical patent/JP2013515079A5/ja
Pending legal-status Critical Current

Links

JP2012546164A 2009-12-22 2010-12-21 低レベルの病原性シュードモナス・エルギノーサ（Ｐｓｅｕｄｏｍｏｎａｓａｅｒｕｇｉｎｏｓａ）感染症を有する患者のスタフィロコッカス（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ）感染症を治療する方法 Pending JP2013515079A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28897709P 2009-12-22 2009-12-22
US61/288,977 2009-12-22
PCT/US2010/061636 WO2011087799A1 (en) 2009-12-22 2010-12-21 A method of treating a staphylococcus infection in a patient having a low-level pathogenic pseudomonas aeruginosa infection

Publications (2)

Publication Number Publication Date
JP2013515079A JP2013515079A (ja) 2013-05-02
JP2013515079A5 true JP2013515079A5 (enExample) 2014-05-29

Family

ID=44224810

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012546164A Pending JP2013515079A (ja) 2009-12-22 2010-12-21 低レベルの病原性シュードモナス・エルギノーサ（Ｐｓｅｕｄｏｍｏｎａｓａｅｒｕｇｉｎｏｓａ）感染症を有する患者のスタフィロコッカス（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ）感染症を治療する方法

Country Status (5)

Country Link
US (1) US8642039B2 (enExample)
EP (1) EP2515935A4 (enExample)
JP (1) JP2013515079A (enExample)
CA (1) CA2784033A1 (enExample)
WO (1) WO2011087799A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2667791A1 (en) * 2006-10-25 2008-05-02 Revalesio Corporation Methods of therapeutic treatment of eyes and other human tissues using an oxygen-enriched solution
US9745567B2 (en) 2008-04-28 2017-08-29 Revalesio Corporation Compositions and methods for treating multiple sclerosis
US20100310665A1 (en) * 2007-10-25 2010-12-09 Revalesio Corporation Bacteriostatic or bacteriocidal compositions and methods
US10125359B2 (en) 2007-10-25 2018-11-13 Revalesio Corporation Compositions and methods for treating inflammation
US9523090B2 (en) 2007-10-25 2016-12-20 Revalesio Corporation Compositions and methods for treating inflammation
US20090263495A1 (en) * 2007-10-25 2009-10-22 Revalesio Corporation Bacteriostatic or bacteriocidal compositions and methods
US8815292B2 (en) 2009-04-27 2014-08-26 Revalesio Corporation Compositions and methods for treating insulin resistance and diabetes mellitus
CN104983740A (zh) 2010-05-07 2015-10-21 利发利希奥公司 用于增强生理性能和恢复时间的组合物和方法
JP2013533320A (ja) 2010-08-12 2013-08-22 レバレジオ コーポレイション タウオパチーを治療するための組成物および方法
RU2014100111A (ru) 2011-06-10 2015-07-20 МЕДИММЬЮН, ЭлЭлСи МОЛЕКУЛЫ, СВЯЗЫВАЮЩИЕСЯ С Psl Pseudomonas, И ПУТИ ИХ ПРИМЕНЕНИЯ
HRP20201370T1 (hr) 2011-11-07 2020-11-27 Medimmune Limited Kombinacijske terapije koje koriste anti-pseudomonas psl i pcrv vezujuće molekule
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
ES2846881T3 (es) * 2015-05-01 2021-07-30 Inhibrx Inc Moléculas que se dirigen al sistema de secreción de tipo III
CN113811544A (zh) 2019-03-13 2021-12-17 免疫医疗有限责任公司 减少定殖患者中的金黄色葡萄球菌感染
CN118620074A (zh) * 2020-06-01 2024-09-10 北京三诺佳邑生物技术有限责任公司 特异性识别假单胞菌pcrv的抗体及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1666058B1 (en) 1998-11-25 2011-12-28 MCW Research Foundation, Incorporated Method of diagnosing a Pseudomonas aeruginosa infection
ES2388420T3 (es) * 2004-05-17 2012-10-15 Gilead Sciences, Inc. Combinación de fosfomicina/aminoglucósido aerosolizada para el tratamiento de las infecciones respiratorias bacterianas
US20060228384A1 (en) * 2005-04-06 2006-10-12 Sequoia Sciences, Inc. Control of biofilm with a biofilm inhibitor
US8268347B1 (en) * 2006-10-24 2012-09-18 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
MX2010003263A (es) * 2007-09-25 2010-06-02 Novartis Ag Tratamiento de trastornos pulmonares con medicamentos aerosolizados tales como vancomicina.
BRPI0819598A2 (pt) * 2007-11-30 2017-05-09 Kalobios Pharmaceuticals Inc anticorpos para o antígeno pcrv da pseudomonas aeruginosa
CA2751433A1 (en) 2009-02-04 2010-08-12 Kalobios Pharmaceuticals, Inc. Combination antibiotic and antibody therapy for the treatment of pseudomonas aeruginosa infection

Similar Documents

Publication Publication Date Title
JP2013515079A5 (enExample)
JP2021063090A5 (enExample)
JP2017519768A5 (enExample)
JP6845016B2 (ja) 多細菌性感染の治療
US20240350634A1 (en) Monoclonal antibody and vaccine targeting filamentous bacteriophage
US8653242B2 (en) Therapeutic antibodies against flagellated Pseudomonas aeruginosa
JP2022512647A5 (enExample)
JP2019031567A5 (enExample)
SI3064511T1 (en) THE MEDICINE USE OF HUMAN HIGHLIGHTS FOR HUMAN RECEPTOR IL-4
JP2009511480A5 (enExample)
JP2016507470A5 (enExample)
JP2011506483A5 (enExample)
JP2005516044A (ja) モノクローナル抗体の鼻内投与によるブドウ球菌の鼻コロニー形成を阻止又は緩和する方法
JP2006511516A5 (enExample)
KR20100021577A (ko) 에스.아우레우스 ＯＲＦ0657ｎ을 표적화하는 항원 결합 단백질
JP2017515473A5 (enExample)
WO2021052461A1 (zh) 抗α-溶血素的抗体及其应用
JP2022536469A5 (enExample)
JP2006514636A5 (enExample)
JP7110095B2 (ja) 院内肺炎を予防または治療する方法
CN104870472A (zh) 抗空肠弯曲杆菌抗体及其用途
JP2018529661A5 (enExample)
JP2012516897A5 (enExample)
JP2024524895A5 (enExample)
JP2002501487A (ja) トリの抗体の使用法